TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with established atrial fibrillation (AF) and bradycardia on long term (\>3 weeks) therapeutic oral anticoagulant (OAC) with warfarin or another OAC who are undergoing new pacemaker system implant or existing pacemaker system revision.~* Subjects with newly detected bradycardia -tachycardia syndrome and AF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic international normalized ratio (INR) and no thrombus on trans-esophageal echocardiogram (TEE) who are undergoing a new pacemaker system implant or revision.~* Subjects with AF and ventricular tachyarrhythmias (VT or VF) or acquired structural heart disease who are candidates for implantable cardioverter-defibrillator (ICD) therapy and are on long term (\>3 weeks) therapeutic OAC with warfarin or another OAC who are undergoing new ICD system implant or existing ICD system revision.~* Subjects with newly detected AF with VT or VF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic INR and no thrombus on TEE who are undergoing ICD system implant or revision~Exclusion Criteria:~* Clinically significant valvular heart disease~* Subjects requiring cardiovascular implantable electrical device (CIED) lead extraction e.g. for device site infection, endocarditis, leads under advisory or other conditions warranting lead(s) system extraction.~* Recent (\<1 month) myocardial infarction~* Documented left atrial (LA) thrombus on TEE~* Contraindications to anticoagulant therapy or adverse event with prior warfarin or edoxaban therapy~* Creatinine clearance \<30ml/min or \>95 ml/min~* Hepatic disease, advanced~* Recent stroke (\<3 months) or thromboembolic event~* Recent (\<3months) intracranial or other major bleeding event~* Use of concomitant dual antiplatelet therapy or other oral, subcutaneous or parenteral anticoagulant therapy~* Subjects on warfarin without therapeutic INR levels before study entry~* Subjects with other clinically significant medical condition~* Subjects with life expectancy \< 1 year~* Lead extraction procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban (Type: EXPERIMENTAL): Edoxaban 30 or 60 mg
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin 1 -1 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Foundation Knee Study - Retrospective

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have knee joint disease related to one or more of the following~  * osteoarthritis~ * post-traumatic arthritis~ * inflammatory tissue disorders~ * arthritis secondary to other diseases~ * Avascular necrosis of the femoral condyles;~* Skeletal maturity~* Less than 70 on the Knee Society Score (rating score)~* Sufficient bone stock, as judged by radiographs, to support primary knee implant~* Sufficient collateral ligaments to support the device, as judged by physician during stability testing (varus/valgus and flexion/extension) and less than 45 degree varus/valgus deformity and/or 90 degree flexion contracture~* Patient is likely to be available for evaluation for the duration of the study~* Able and willing to sign the informed consent and follow study procedures~* Patient is not pregnant~* No infection present~* No known materials sensitivity~Exclusion Criteria:~* Skeletal immaturity~* Greater than or equal to 70 on preoperative Knee Society Score (Rating Score)~* Post-patellectomy~* Insufficient bone quality which may affect implant stability~* Insufficient collateral ligaments, as judged by the physician. Greater than 45 degree varus/valgus deformity and/or 90 degree flexion contracture.~* Neurological conditions that might hinder patient's ability to follow study procedures (i.e., any that restrict physical activities such as Parkinson's Disease, Multiple Sclerosis, previous stroke which affects lower extremity)~* Mental conditions that may interfere with ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the patient cannot understand the informed consent process, global dementia, prior strokes that interfere with the patient's cognitive abilities, senile dementia, and Alzheimer's Disease)~* Prisoners~* Conditions that place excessive demand on the implant (i.e. Charcot's joints, muscle deficiencies, refusal to modify postoperative physical activities, skeletal immaturity)~* Patient is pregnant~* Infection present~* Materials sensitivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foundation Knee (Type: None): Retrospective data collection on 510(k) approved device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Positive COVID 19 test or clear clinical diagnosis of COVID-19. Positive COVID-19 test will be confirmed based on a PCR or antigen test result or patient reported history. Clear clinical diagnosis of COVID-19 will be a combination of respiratory symptoms and clinical findings based on laboratory values and radiographs.~3. Moderate to severe hypoxemia defined by a baseline supplemental oxygen requirement of 6 liters or higher (including high flow oxygenation devices) as measured within the 24 hours before enrollment~Exclusion Criteria:~1. Pregnancy~2. Untreated pneumothorax, which must be evaluated with a baseline chest radiograph or computerized tomography scan at least 72 hours prior to enrollment~3. Presence of pneumomediastinum, pneumopericardium, significant subcutaneous emphysema, or pulmonary blebs, which should also be evaluated with a baseline chest radiograph prior to enrollment~4. Current invasive mechanical ventilation~5. Current non-invasive mechanical ventilation~6. Any patient who will not be stable for transport to the hyperbaric chamber, in addition to any relative contraindications identified by the treating hyperbaric physician or inpatient hospital team (e.g., severely impaired cardiac output due to significant myocardial injury).~7. Any patient without the capacity to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperbaric Oxygen (Type: EXPERIMENTAL): Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
- Standard of Care (Type: NO_INTERVENTION): Standard of Care (SOC) as defined by current best practice treatments for COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Recipient Inclusion Criteria:~1. Adult patients \> or = 18 years of age~2. Actively listed for Liver Transplant (LT) or Simultaneous Liver and Kidney (SLK)~3. Current HCV NAT- status~4. Review by multi-disciplinary transplant team that patient is appropriate for listing for HCV NAT+ liver offers~Recipient Exclusion Criteria:~1. Unwilling to consent to post transplant DAA therapy~2. Hepatitis B Virus (HBV) viremia~Donor Inclusion Criteria:~1. HCV NAT+~2. Deceased Donor organs~3. HBV cAb donors will be considered on a case by case basis based on specific recipient factors and plan for post-transplant prophylaxis~Donor Exclusion Criteria:~1. Bilirubin \>3~2. Positive nucleotide testing for HBV~3. Radiographic, laboratory or other clinical evidence of portal hypertension~4. Fibrosis on pre-procurement liver biopsy fibrosis \> F1 or fibroscan \>7 (if both are done and discordant, use biopsy to determine eligibility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients who received a HCV+ liver transplant (Type: None): Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
- Patients who received a HCV- liver transplant (Type: None): Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Registry of Patients With Ulcerative Colitis in Germany

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe Ulcerative Colitis aged 18-80 years at enrollment~* Written informed consent is given~Exclusion Criteria:~* Malignant disease in history (except for non-melanoma skin cancer)~* Any contraindication according to the SmPC of the respective medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Study Arms:
- Group 1 (Type: None): UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
- Group 2 (Type: None): UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Participated in the MSK-002 study~2. Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.~3. Female patients of childbearing potential must have a negative pregnancy test (urine human chorionic gonadotropin \[HCG\] at the end of MSK-002 study); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.~4. Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.~Individuals who met any of the exclusion criteria in the original protocol or those listed below are not eligible to participate in the study:~1. Epilepsy and currently on medication.~2. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator.~3. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.~4. Intolerable amifampridine-related side effects~5. Treatment with an investigational drug (other than amifampridine) or device while participating in this study.~6. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amifampridine phosphate (Type: EXPERIMENTAL): tablets equivalent to 10mg amifampridine, 3 to 4 times per day. Initially, the daily amifampridine doses were to be the doses that were determined at the end of the Run-in Period from the MSK-002 study. The usual range was from 30 to 80 mg total daily dose, given in three (3) or four (4) doses, with no single dose \> 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with advanced CTCL~* Have had at least 2 systemic therapies~* Must have evaluable disease~* Eastern Cooperative Oncology Group performance status 0-2~* Adequate bone marrow, hepatic and renal function~* At least 3 weeks from prior therapies~* Not receiving topical steroids or have been on a stable dose of topical steroids for at least 2 weeks~* Able to swallow capsules~* At least 3 weeks from major surgery~* Agree to practice effective contraception~* Able to understand and willing to sign the informed consent form~Exclusion Criteria:~* Receiving systemic steroids~* Receiving topical or systemic retinoids or vitamin A~* Receiving radiotherapy, biological therapy,or any other investigational agents~* Uncontrolled intercurrent illness~* Pregnant or lactating women~* Known to be HIV-positive~* Active hepatitis B and/or hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: High dose (Type: EXPERIMENTAL): High-dose (Arm A): 200 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
- Arm B: High dose (Type: EXPERIMENTAL): Low-dose (Arm B): 100 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and/or radiologically confirmed advanced HCC~* Detectable HCV RNA with anti-HCV-positivity~* Life expectancy of at least 3 months~* Willing to use adequate contraception~Exclusion Criteria:~* Pregnant or breastfeeding~* Undetectable HCV RNA~* Uncontrolled hypertension~* Active or clinically significant cardiac disease~* Thrombolic, embolic, venous or arterial events within 6 months of informed consent~* Pulmonary hemorrhage/bleeding event (NCI-CTCAE grade 2 or higher) within 4 weeks before study entry~* Previously untreated or concurrent cancer except cervical cancer in situ, treated basal cell carcinoma or superficial bladder tumor~* Presence of non-healing wound, ulcer or bone fracture~* History of organ allograft~* Known or suspected allergy or hypersensitivity to any of the study drugs~* Any malabsorption condition~* Inability to comply with the protocol and/or not willing or not available for follow up~* Major surgery within 30 days prior to start of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Sorafenib taken orally twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Ultrasound to Predict the Results of Draining Pleural Effusions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The participant is willing and able to give informed consent for participation in the study.~* Adult male or female, aged 18 years or above.~* Diagnosed with a symptomatic pleural effusion requiring either diagnostic and/or therapeutic pleural aspiration or drainage.~* Expectation by the clinician responsible for assessing the patient that more than 500mL of pleural fluid will be drained on this particular occasion.~Exclusion Criteria:~* Age less than 18 years~* Inability to provide informed consent~* Evidence of significant septation or loculation within the pleural effusion as determined by the clinician responsible for assessing the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Those aged 18 years of age~* Presenting to a HCP with low back pain~* Able to speak, write, and understand both verbal and written English~Exclusion Criteria:~* Conditions that may impede the patient's ability to participate in painPRIMER and complete the questionnaires, as per the HCP's discretion~* Patients presenting who have undergone surgery for back pain in the previous 12 months~  * Patients with Medicare as their primary insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- painPREMIER cohort (Type: None): None
- Control cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hernia Repair in Multiply Morbid Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults of either gender~* must have 2 or more co-morbidities~Exclusion Criteria:~* local or systemic infection~* expected survival of \<24 months~* non-ambulatory

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Strattice Reconstructive Tissue Matrix (Type: EXPERIMENTAL): Use of Strattice Reconstructive Tissue Matrix to support hernia repair
- Proceed Surgical Mesh (Type: ACTIVE_COMPARATOR): Use of Proceed Surgical Mesh to support hernia repair

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age equal to or over 18 years old,~* Patients with proved hereditary hemochromatosis with homozygosity for the C282Y mutation of the HFE gene,~* Patients with rheumatism related to hemochromatosis, considered by the rheumatologist refractory to usual treatment defined by a persistent painful symptomatology despite a treatment of at least one month with level 2 analgesics (weak opioids) at maximal dose, NSAID, colchicine, steroid injection or a combination of these treatments,~* Patients with pain \> 40/100mm measured by VAS (pain of the last 48 hours),~* Effective contraception to be used during treatment and until 48h after the last administration for women of reproductive age,~* Patients who have given written informed consent.~Exclusion Criteria:~* Other cause of inflammatory rheumatisms such as Rheumatoid Arthritis, Spondyloarthropathies, psoriatic arthritis, or systemic diseases,~* Ongoing treatment with Methotrexate, Hydroxychloroquine, biologic or immunosuppressive drugs~* Malignant pathology, monoclonal gammopathy,~* Intolerance to anakinra,~* Contraindications to the use of anakinra: pregnancy or breastfeeding, hypersensitivity to any of the excipients or to proteins from E. coli, severe renal impairment (creatinine clearance \<30 ml / minute), neutropenia (neutrophil count \<1.5 x 109 / l), ongoing infection~* Patients that cannot follow the protocol,~* Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues